TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22245162

Group type: EXPERIMENTAL
Intervention: Bench step exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 20930279

Group type: EXPERIMENTAL
Intervention: High-dose phenserine (10 and 15 mg BID)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: High-dose phenserine (more than 12 weeks)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: High-dose phenserine (after 12 weeks)
Number of subjects: 164
Study: 17389347

Group type: EXPERIMENTAL
Intervention: Hindsight group (informed of suicide or homicide occurring after release)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (withheld outcome information)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: AAPL members
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Non-AAPL members
Number of subjects: 235
Study: 16361622

Group type: EXPERIMENTAL
Intervention: Docetaxel 85 mg/m2 on day 8 plus gemcitabine 800 mg/m2 on days 1 and 8 (arm A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 on day 1 plus cisplatin 75 mg/m2 on day 1 (arm B)
Number of subjects: 96
Study: 12036812

Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: sodium caseinate (control diet)
Number of subjects: 23
Study: 10379016

Group type: COMPARATOR
Intervention: Butter-enriched diet (high in saturated fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soybean oil diet (0.5 g trans fatty acid per 100 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soft margarine diet (7.4 g trans fatty acid per 100 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shortening diet (9.9 g trans fatty acid per 100 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stick margarine diet (20.1 g trans fatty acid per 100 g)
Number of subjects: 36
Study: 8339102

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 34
Study: 2436423

Group type: EXPERIMENTAL
Intervention: 1% 11a-hydroxyprogesterone lotion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 10
Study: 31721143

Group type: EXPERIMENTAL
Intervention: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30728339

Group type: EXPERIMENTAL
Intervention: ICS + LTRA
Number of subjects: 28

Group type: COMPARATOR
Intervention: ICS
Number of subjects: 28
Study: 27266769

Group type: EXPERIMENTAL
Intervention: Advance directive that defaults to comfort care, enabling patients to opt into life-extending care
Number of subjects: 270

Group type: COMPARATOR
Intervention: Advance directive that defaults to life-extending care, enabling patients to opt out from such care
Number of subjects: 270

Group type: COMPARATOR
Intervention: Traditional advance directive that requires patients to actively choose their goals of care
Number of subjects: 270
Study: 25342408

Group type: EXPERIMENTAL
Intervention: Doppler-guided goal-directed fluid therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Restrictive fluid therapy
Number of subjects: 56
Study: 22418065

Group type: EXPERIMENTAL
Intervention: MP29-02 (azelastine and fluticasone propionate)
Number of subjects: 3398

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 3398

Group type: COMPARATOR
Intervention: Azelastine
Number of subjects: 3398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3398
Study: 20576734

Group type: EXPERIMENTAL
Intervention: Intensive communication system (ICS) with family meetings within 5 days of ICU admission and weekly thereafter
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Intensive communication system (ICS)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Usual care and communication (Control)
Number of subjects: 481
Study: 18004131

Group type: EXPERIMENTAL
Intervention: GHB (40 or 60 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol (0.7 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15617670

Group type: EXPERIMENTAL
Intervention: Naming actions as verbs in citation form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naming actions as verbs inflected for third person singular or plural
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (naming actions with unrelated distracters)
Number of subjects: 0
Study: 12062456

Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg bid)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 10202741

Group type: EXPERIMENTAL
Intervention: Transdermal 17-beta estradiol 50 micrograms/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound 3.32 g/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Transdermal 17-beta estradiol 50 micrograms/d plus Ossein-hydroxyapatite compound 3.32 g/d
Number of subjects: 96

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 96
Study: 8596479

Group type: EXPERIMENTAL
Intervention: Standardized incremental exercise test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normoglycemic diabetic patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hyperglycemic diabetic patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Submaximal levels of power output
Number of subjects: 16
Study: 1771100

Group type: EXPERIMENTAL
Intervention: Etozolin (200 mg, 400 mg, 600 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg, 50 mg, 75 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7200737

Group type: EXPERIMENTAL
Intervention: Epidural morphine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg)
Number of subjects: 10
Study: 30657812

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (temperature, 33.0 ± 1.0°C) maintained for at least 72 hours after hemicraniectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 50
Study: 28084889

Group type: EXPERIMENTAL
Intervention: Screened population (FOBT screening)
Number of subjects: 500000

Group type: COMPARATOR
Intervention: Control population (no screening)
Number of subjects: 500000
Study: 25922302

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23350696

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) insulin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intravenous (IV) insulin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 21457235

Group type: EXPERIMENTAL
Intervention: MAP0004 (0.63 mg emitted dose; 1.0 mg nominal dose)
Number of subjects: 903
Study: 19629292

Group type: EXPERIMENTAL
Intervention: Physical exercise program (PEP): 40 minutes of aerobic exercises performed 3x/week for 3 months at 70% of VO2max, and muscular exercises at 40% of maximal voluntary contraction (MVC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (CG): No participation in the physical exercise program
Number of subjects: 88
Study: 17359519

Group type: EXPERIMENTAL
Intervention: Two auricular acupressure beads (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One auricular acupressure bead (Group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No additional therapy (Group C)
Number of subjects: 24
Study: 15013599

Group type: EXPERIMENTAL
Intervention: 20 Hz electrical stimulation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 80 Hz electrical stimulation
Number of subjects: 7
Study: 11511435

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (atrio-bi-ventricular)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control (optimal medical therapy with diuretics, ACE inhibitors, and beta-blockers)
Number of subjects: 800
Study: 9612361

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-free treatment (Control)
Number of subjects: 0
Study: 9171755

Group type: EXPERIMENTAL
Intervention: Surgeons certified specialists for at least 10 years
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: University hospitals
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1399
Study: 2694740

Group type: EXPERIMENTAL
Intervention: Gestrinone (2.5-5 mg, orally or by vaginal pessary, two or three times weekly)
Number of subjects: 300
Study: 840133

Group type: EXPERIMENTAL
Intervention: Beta-escin (Reparil)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 53
Study: 30929275

Group type: EXPERIMENTAL
Intervention: Valproic acid (0-8 mM)
Number of subjects: 0
Study: 28960230

Group type: EXPERIMENTAL
Intervention: Low BMD with sarcopenia
Number of subjects: 10937

Group type: EXPERIMENTAL
Intervention: Low BMD without sarcopenia
Number of subjects: 10937

Group type: COMPARATOR
Intervention: Sarcopenia alone
Number of subjects: 10937
Study: 25583412

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sutureless securement device
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control usual practice polyurethane dressing
Number of subjects: 123
Study: 24197399

Group type: EXPERIMENTAL
Intervention: Interactive, 7-week web-based intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard medical care as usual (Control)
Number of subjects: 59
Study: 21737467

Group type: EXPERIMENTAL
Intervention: PPH-01
Number of subjects: 425

Group type: COMPARATOR
Intervention: PPH-03
Number of subjects: 425
Study: 19583646

Group type: EXPERIMENTAL
Intervention: Meridian acupressure applied every day for 10 min for two weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 56
Study: 17603225

Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg once-daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glimepiride 1 mg twice-daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg once-daily and 1 mg twice-daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 8
Study: 15051842

Group type: EXPERIMENTAL
Intervention: IVF crispy bars
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control crispy bars
Number of subjects: 48
Study: 11561495

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Internal Fixation
Number of subjects: 99
Study: 9988026

Group type: EXPERIMENTAL
Intervention: Body-surface mapping (BSM)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Combined results of BSM in a two-step algorithm
Number of subjects: 635
Study: 7848799

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 5
Study: 3075109

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day for 5 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30444801

Group type: EXPERIMENTAL
Intervention: Foot massage (10 minutes, 5 minutes per leg, using sweet almond oil)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 66
Study: 29231584

Group type: EXPERIMENTAL
Intervention: Electrothermal acupuncture at zusanli (ST 36) for 30 min once a day for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Granisetron hydrochloride injection, 3 mg before and after cisplatin chemotherapy, for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electrothermal acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Granisetron hydrochloride injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26186566

Group type: EXPERIMENTAL
Intervention: 150,000 IU cholecalciferol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 300,000 IU cholecalciferol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both doses of cholecalciferol
Number of subjects: 50
Study: 23925936

Group type: EXPERIMENTAL
Intervention: Combined splint/stretching intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normative data (age- and sex-matched)
Number of subjects: 124
Study: 21903745

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with cisplatin (100 mg/m2 on days 1 and 29, vinblastine at 5 mg/m2 per week for 5 weeks) and TRT (63 Gy delivered as once-daily fractions beginning on day 50)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Concurrent chemotherapy with cisplatin (100 mg/m2) and TRT (63 Gy delivered as once-daily fractions beginning on day 1)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Concurrent chemotherapy with cisplatin (50 mg/m2 on days 1, 8, 29, and 36) and oral etoposide (50 mg twice daily for 10 weeks on days 1, 2, 5, and 6) with TRT (69.6 Gy delivered as 1.2 Gy twice-daily fractions beginning on day 1)
Number of subjects: 610
Study: 19247655

Group type: EXPERIMENTAL
Intervention: 100 mg/d aspirin
Number of subjects: 98
Study: 16676655

Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg, orally) administered after landing approximately 1 h before testing
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no midodrine)
Number of subjects: 5
Study: 15316165

Group type: EXPERIMENTAL
Intervention: 1 mg/day oral finasteride for 12 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: 5% topical minoxidil solution applied twice daily for 12 months
Number of subjects: 65
Study: 10936980

Group type: EXPERIMENTAL
Intervention: Prematil
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Humana‐0
Number of subjects: 75

Group type: COMPARATOR
Intervention: All formulas
Number of subjects: 75
Study: 9355069

Group type: EXPERIMENTAL
Intervention: MCNS‐FSGS group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FSGS‐R group (first biopsies during nephrotic stage)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FSGS patients in remission
Number of subjects: 14

Group type: COMPARATOR
Intervention: FSGS during nephrotic and remission stages
Number of subjects: 14
Study: 1546900

Group type: EXPERIMENTAL
Intervention: Closed suction drainage (DG)
Number of subjects: 227

Group type: COMPARATOR
Intervention: No drain (NDG)
Number of subjects: 227
Study: 3838401

Group type: EXPERIMENTAL
Intervention: molsidomine (2 mg intravenously)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (ISDN) (5 mg sublingually)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg sublingually)
Number of subjects: 30
Study: 31612309

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 29969520

Group type: EXPERIMENTAL
Intervention: IATP-R
Number of subjects: 30
Study: 27287235

Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy (50 mg/day)
Number of subjects: 28
Study: 24933430

Group type: EXPERIMENTAL
Intervention: 6% CHO‐electrolyte solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Electrolyte (placebo) solution
Number of subjects: 10
Study: 23509529

Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Canadian Fabry Disease Initiative (CFDI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CFDI
Number of subjects: 18
Study: 19854432

Group type: EXPERIMENTAL
Intervention: Office ergonomics program implemented from 1995 to 2007
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Office ergonomics program with a 50-50 cost share agreement for office equipment purchases starting in 1999
Number of subjects: 0
Study: 18157595

Group type: EXPERIMENTAL
Intervention: Symphytum herb extract cream (10% active ingredient)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Reference product (1% active ingredient)
Number of subjects: 278
Study: 16185409

Group type: EXPERIMENTAL
Intervention: Negative charge aerosol (NCA) treatment for 1.5 hours, 1-2 times a day, from 6 postburn hours to 2 postburn days.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Negative charge aerosol (NCA) treatment in self control group with sterile schissel coverage.
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Negative charge aerosol (NCA) treatment in trial group.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Conventional treatment in control group.
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Pathological examination in rats treated with NCA.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Pathological examination in rats treated with conventional treatment.
Number of subjects: 310
Study: 12578249

Group type: EXPERIMENTAL
Intervention: Metaphorical verbal instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Movement-relevant verbal instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: None verbal instruction
Number of subjects: 60
Study: 9720483

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha-tocopherol (vitamin E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selegiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postmenopausal estrogen replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 0
Study: 7642014

Group type: EXPERIMENTAL
Intervention: Holter monitoring showing > 10 VEB/hour
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Holter monitoring showing couplets
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Holter monitoring showing nonsustained ventricular tachycardia (NSVT)
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Holter monitoring showing any complex ventricular arrhythmia
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Left ventricular dysfunction
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Frequent ventricular arrhythmias (VA)
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Couplets
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Complex ventricular arrhythmias (VA)
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 8676

Group type: EXPERIMENTAL
Intervention: Overall predictive power of ventricular arrhythmias (VA)
Number of subjects: 8676
Study: 2769837

Group type: EXPERIMENTAL
Intervention: Aspiration of middle ear effusions prior to ventilation tube insertion
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-aspirated ears (control)
Number of subjects: 55
Study: 320995

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurandrenolone ointment
Number of subjects: 0
Study: 31843628

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active placebo (remifentanil)
Number of subjects: 30
Study: 30407136

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Yohimbine (both drugs)
Number of subjects: 0
Study: 29056008

Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α‐2b (Y shape, 40 kD) injection (180 μg/week)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Peg‐IFN‐α‐2a (control)
Number of subjects: 820
Study: 26230745

Group type: EXPERIMENTAL
Intervention: Programmed physical exertion during recovery from concussion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of exertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 0
Study: 23809140

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-nucleosidic reverse transcriptase inhibitor (NNRTI)
Number of subjects: 35
Study: 20709708

Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Percutaneous A1 pulley release
Number of subjects: 95
Study: 19366774

Group type: EXPERIMENTAL
Intervention: Screened with adenosine‐stress radionuclide myocardial perfusion imaging (MPI)
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Not screened
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Screened with normal MPI results
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Screened with moderate or large MPI defects
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: Screened
Number of subjects: 1123
Study: 17014541

Group type: EXPERIMENTAL
Intervention: Xeno III (self-etching priming agent)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phosphoric acid etch with Prime & Bond (traditional acid etch)
Number of subjects: 60
Study: 15486377

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Salmeterol, 50 microg bid
Number of subjects: 18
Study: 11003204

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Naltrexone 0 mg/day (placebo)
Number of subjects: 23
Study: 9306297

Group type: EXPERIMENTAL
Intervention: Progressive relaxation and visualization treatment (6 hour-long sessions over 3 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Psychoeducational addiction treatment group
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (visualization and psychoeducation)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Visualization sessions
Number of subjects: 76
Study: 8320604

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant administration
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endotracheal suctioning
Number of subjects: 25
Study: 3578725

Group type: EXPERIMENTAL
Intervention: Fentanyl 3.0 micrograms/kg (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol 0.1 mg/kg with fentanyl 3.0 micrograms/kg (group 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halothane 0.5% inspired concentration (group 3)
Number of subjects: 0
Study: 29860964

Group type: EXPERIMENTAL
Intervention: 8-week group cognitive behavioral stress management intervention
Number of subjects: 29